利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2468 条记录 (耗时 0.033 秒)

    ETUI ZUR AUFNAHME EINER ARZNEIMITTELPACKUNG SOWIE DEREN VERWENDUNG
    1.
    发明授权
    ETUI ZUR AUFNAHME EINER ARZNEIMITTELPACKUNG SOWIE DEREN VERWENDUNG 有权
    CASE用于接收包装药品及其使用

    公开(公告)号：EP1898863B1

    公开(公告)日：2011-06-22

    申请号：EP06818215.3

    申请日：2006-06-27

    申请人： Schering Aktiengesellschaft

    发明人： LEIFELD, Sabine

    IPC分类号： A61J7/04 ,  B65D75/00

    CPC分类号： B65D73/0035 ,  A61J1/035 ,  A61J7/04

    摘要： The invention relates to a case for accommodating a blister pack, the case comprising a first half and a second half. The halves are articulated on one another. The first half of the case is designed as a pocket for accommodating the blister pack and has an outer part and an inner, transparent part as well as first through-passages in the transparent part and second through-passages in the outer part. The first through-passages are aligned, at least in part, with the second through-passages, at least where the containers are located once the blister pack has been accommodated in the pocket. The second half of the case has a first compartment for accommodating a first indicating means, which indicates days of the week, and first windows for displaying the days of the week on an inner transparent surface of the second half of the case in the region of the first compartment. The first windows are arranged such that they are aligned with the columns of containers of a medicament pack accommodated in the pocket.

    REDUCTION OF RESTENOSIS
    3.
    发明公开
    REDUCTION OF RESTENOSIS 审中-公开
    降低再狭窄

    公开(公告)号：EP1951332A1

    公开(公告)日：2008-08-06

    申请号：EP06792428.2

    申请日：2006-10-11

    申请人： Schering Aktiengesellschaft

    发明人： KRAUSE, Werner

    IPC分类号： A61L29/16 ,  A61F2/06 ,  A61K39/00

    CPC分类号： A61L31/16 ,  A61K2039/505 ,  A61L2300/256 ,  A61L2300/426 ,  C07K16/2893

    摘要： A method of reducing restenosis comprises administering to a patient a stent and reducing, shutting down or modifiying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the stent. Alternatively, an ex-vivo procedure may be used.